Comparing Treatment of Dry Eye With Intracanlicular Dexamethasone, Restasis, and/or Lotemax

• Status: Recruiting
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This 6 month study seeks to compare the use of Intracanalicular Dexamethasone in conjunction with Restasis (cyclosporine ophthalmic emulsion) for the treatment of signs and symptoms of dry eye disease as compared to Restasis with Lotemax (loteprednol etabonate ophthalmic suspension 0.5%) and Restasis monotherapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Thomas Chester, OD
• Treatments: Cyclosporine; Cyclosporins; Dexamethasone; Loteprednol Etabonate

Criteria

Inclusion Criteria:

• 18 years of age or older

• Signs and symptoms of DED

• Consent to treat with topical immunomodulator

• Willing and able to comply with clinic visits and study related procedures

• Willing and able to sign the informed consent form

Exclusion Criteria:

• Patients under the age of 18.

• Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)

• Active infectious systemic disease

• Active infectious ocular or extraocular disease

• Altered nasolacrimal flow of either acquired, induced, or congenital origin

• Hypersensitivity to dexamethasone

• Patients who have been on topical immunomodulating agents in the previous 3 months to their baseline visit

• Patient being treated with either topical, oral, or intravenous immunosuppressive agents, immunomodulating agents, or steroid (including NSAIDS)

• Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator